UX DA001
Alternative Names: Human midbrain dopaminergic progenitor cells injection - Shanghai UniXell Biotechnology; UX-DA001Latest Information Update: 02 May 2025
At a glance
- Originator Shanghai UniXell Biotechnology
- Class Stem cell therapies
- Mechanism of Action Dopaminergic cell replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Parkinson's disease
Most Recent Events
- 01 Mar 2025 Phase-I clinical trials in Parkinson's disease (Treatment-experienced) in China (Implant) (NCT06778265)